Bad News For Competitor Turns Into Big Win For ARS Pharma Stock
I'm PortAI, I can summarize articles.
ARS Pharmaceuticals Inc. stock surged 18.86% to $13.01 after the FDA identified deficiencies in rival Aquestive's drug application, delaying competition in the needle-free epinephrine market. Analyst William Blair noted this news is positive for ARS, as it allows more time for its product, neffy, to establish itself. ARS has also petitioned the FDA to delay approval of Aquestive's Anaphylm, citing safety concerns. Blair maintains an Outperform rating on ARS shares, highlighting the company's strong potential and funding for the product launch.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments